Publications

Biopticon in the Press

  1. Patents are awarded to companies where TumorImagerTM is used:
    • Gilead Patent 20160075695 to Gilead for BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS
      http://www.patentsencyclopedia.com/app/20160075695
      Body weights and tumor volume were monitored with a laser scan system, Biopticon Tumorimager (Biopticon), and recorded two times per week. Clinical signs were monitored daily during the dosing phase of the study. All animals were sacrificed by carbon dioxide exposure at designated time points.
    • Merck Patent 20140286946 to in 2014 Merck researches for METHOD FOR PREPARIN ANTIBODIES HAVING IMPROVED PROPERTIES 
      http://www.patentsencyclopedia.com/app/20140286946
      A week after implantation, the tumors were evaluated by 3-dimensional measurements using Biopticon Tumorlmager and randomized into treatment groups. Groups of five mice each were treated with indicated doses of antibodies in a weekly treatment regimen for 3 consecutive weeks.
    • Mallinckrodt LLC Patent 20140271820 to LIPOSOME OXALIPLATIN COMPOSITIONS FOR CANCER THERAPY
      https://patents.google.com/patent/WO2014159760A1/en
      Tumor volume was determined using a tumor imaging system (Biopticon) 2-3 times per week. Body weights were measured weekly. Tumor volume data was analyzed to determine the ratio of treated versus control tumor volumes (%T/C).
  2. The following cancer research institutions announced their services using TMS:
    • Oklahoma Medical Research Center (OMRF) in Oklahoma OK 
      Drug efficacy studies – we evaluate in vivo efficacy of agents either alone or in combination with standard chemotherapy regimens against murine tumors, human tumor xenografts, and transgenic mouse models of human cancer. Tumor size is monitored by caliper measurements or TumorImager system allowing 3-D subcutaneous tumor scanning and/or in vivo imaging (for disseminated and orthotopic models). Tumor monitoring and Imaging – we monitor tumor growth and response to therapy using advanced tumor monitoring (Biopticon TumorImager, TumorManager systems) and imaging technology (IVIS Lumina III imaging system, Living Image, 4.0 Software).
    • Covidien/Mallinckrodt
      http://cancerres.aacrjournals.org/content/75/15_Supplement/4400
      The doses of Taxotere and MNK-010 were based on maximum tolerated dose (MTD) or highest dose tested for a given dose interval. Tumor volume was measured twice per week using the Biopticon tumor imaging system and tumor volume data was analyzed to determine tumor growth delay and partial tumor regression. Survival analysis was conducted and median survival time determined.
    • University of Oklahoma Health Sciences Center
      https://academic.oup.com/glycob/article/27/11/1062/4080184
      Tumor volume was measured every 5 days by a TumorImager (Biopticon Corporation; Princeton, NJ), an image acquisition and processing system that uses laser-scanning measurements to calculate more precise tumor volumes through algorithms.
    • Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918852/pdf/mab.2019.0035.pdf
      Biweekly body weights and tumor volumes were recorded using a three-dimensional subcutaneous tumor scanning device (TumorImager; Biopticon, Princeton, NJ). At the termination of the study, mice were sacrificed by carbon dioxide asphyxiation. Mice were observed daily for clinical signs. Biweekly body weights and tumor volumes were recorded using a three-dimensional subcutaneous tumor scanning device (TumorImager; Biopticon, Princeton, NJ). At the termination of the study, mice were sacrificed by carbon dioxide asphyxiation.
    • BC Cancer Research Institute, Animal Resource Centre (BCCRI, ARC)
      https://animalcare.ubc.ca/acup-newsletter-july-2020
      The Animal Resource Centre is a 20,000 sq ft barrier, with 18 animal holding rooms, and 9 procedure rooms. It continues to promote its imaging equipment including PET/CT, SPECT/CT, Maestro, and SARRP, as well as a Biopticon tumour imager (biopticon.com). We are looking forward to installing a new IVIS, shortly.
    • Gene Expression and Regulation Program, The Wistar Institute
      https://www.nature.com/articles/s41467-020-17127-2
      Randomization was performed using Tumor Manager software (v 3.3.4) by Biopticon. Mice that died for unknown reason (low tumor burden, normal weight, and condition scores) were excluded from analysis.
    • Changhua Christian Hospital, Department of Neurology, Taiwan, Republic of China
      https://www.dovepress.com/antitumor-actions-of-intratumoral-delivery-of-membrane-fused-mitochond-peer-reviewed-fulltext-article-OTT
      After 25 days of treatment, tumorigenesis was evaluated by analyzing the volumes of subcutaneous breast tumors in the mice by using a 3D laser scanning device (TumorImager; Biopticon Corporation, Princeton, NJ, USA) and measuring tumor weights.
    • Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881748/
      Biweekly body weights and tumor volumes were recorded using a three-dimensional subcutaneous tumor scanning device (TumorImager; Biopticon, Princeton, NJ). At the termination of the study, mice were sacrificed by carbon dioxide asphyxiation.
    • The Wistar Institute, Philadelphia, Pennsylvania, USA
      https://doi.org/10.1172/jci.insight.89760
      Once tumor volume reached 70–100 mm3, animals (n = 50) were randomized using Tumor Manager (Biopticon) into 5 treatment groups
    • Changhua Christian Hospital, Department of Neurology
      https://pubmed.ncbi.nlm.nih.gov/32606744/Each group had at least six transplant replicates. After 25 days of treatment, tumorigenesis was evaluated by analyzing the volumes of subcutaneous breast tumors in the mice by using a 3D laser scanning device (TumorImager; Biopticon Corporation, Princeton, NJ, USA) and measuring tumor weights.
    • American Society for Clinical Investigation
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214535/
      Once tumor volume reached 70–100 mm3, animals (n = 50) were randomized using Tumor Manager (Biopticon) into 5 treatment groups: carboplatin (50 mg/kg i.p. injection weekly; Hospira); MK8776 (CHK1i, 50 mg/kg i.p. every 3 days; Selleckchem); AZD2281 (PARPi, 100 mg/kg oral gavage [OG] daily); AZD6738 (ATRi, 50 mg/kg OG daily; AstraZeneca); and vehicle.
    • University of Nebraska Medical Center
      https://aacrjournals.org/mct/article/19/6/1351/169703/A-Novel-Combination-Approach-Targeting-an-Enhanced
      Tumor volume was assessed twice a week using the Biopticon TumorImager. When tumor volume approached 1 cm3, the mice were euthanized using CO2 and tumor tissues were collected and processed for Western blotting and immunohistologic analyses for the expression of key proteins.
    • University of Nebraska Medical Center
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788547/
      Average daily tumor volumes ±SD (n = 5 mice) were then determined by 3D surface scanning, compared at each time point by multiple Mann–Whitney tests (polyplexes), and a rate-based T/C ratio with associated p value was calculated for each polyplex…
    • University of Nebraska Medical Center
      https://www.sciencedirect.com/science/article/abs/pii/S154996342100006X?via%3Dihub
      Tumors were injected SQ to facilitate tumor volume measurements by 3D surface scanning (TumorImager, Biopticon). Tumor volumes and body weights were measured every other day before treatment, then daily until 48 h after the last treatment.